- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Myelofibrosis: Characteristics and Subtypes
Aaron Gerds, MD, MS, reviews myeloid disorder myelofibrosis and presents diverse symptoms, from blood count variations to spleen enlargement.
EP: 1.Myelofibrosis: Characteristics and Subtypes
EP: 2.NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
EP: 3.Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life
EP: 4.Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals
EP: 5.NCCN Guidelines 2023: Updates in Myelofibrosis Management
EP: 6.NCCN Guidelines: Categories and Recommendations in Myelofibrosis
EP: 7.Integrating Momelotinib: NCCN Guidelines and Drug Comparison
EP: 8.Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations
EP: 9.Future of Myelofibrosis: Anticipated Data and Emerging Therapies
This is a video synopsis/summary of a Guidelines featuring Aaron Gerds, MD, MS.
Myelofibrosis, a myeloproliferative neoplasm, manifests in variable blood counts and constitutional symptoms. Gerds explains its impact, causing cytokine-driven symptoms like night sweats and spleen enlargement. The disease's clonal nature poses a risk of progression to the blast phase, a highly aggressive stage. Understanding these clinical aspects is crucial for effective management.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
